Diabetes medications and cardiovascular outcome trials: Lessons learned

Kershaw V. Patel; Natalia De Albuquerque Rocha; Darren K. McGuire

doi:10.3949/ccjm.84gr.17006

Diabetes medications and cardiovascular outcome trials: Lessons learned

Kershaw V. Patel, Natalia De Albuquerque Rocha, Darren K. McGuire

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.

Original language	English (US)
Pages (from-to)	759-767
Number of pages	9
Journal	Cleveland Clinic journal of medicine
Volume	84
Issue number	10
DOIs	https://doi.org/10.3949/ccjm.84gr.17006
State	Published - 2017

ASJC Scopus subject areas

General Medicine

Access to Document

10.3949/ccjm.84gr.17006

Cite this

@article{6c6af12f5dc946efb077cc1f4ab67e93,

title = "Diabetes medications and cardiovascular outcome trials: Lessons learned",

abstract = "The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.",

author = "Patel, \{Kershaw V.\} and Rocha, \{Natalia De Albuquerque\} and McGuire, \{Darren K.\}",

year = "2017",

doi = "10.3949/ccjm.84gr.17006",

language = "English (US)",

volume = "84",

pages = "759--767",

journal = "Cleveland Clinic journal of medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "10",

}

TY - JOUR

T1 - Diabetes medications and cardiovascular outcome trials

T2 - Lessons learned

AU - Patel, Kershaw V.

AU - Rocha, Natalia De Albuquerque

AU - McGuire, Darren K.

PY - 2017

Y1 - 2017

N2 - The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.

AB - The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.

UR - https://www.scopus.com/pages/publications/85030644529

UR - https://www.scopus.com/inward/citedby.url?scp=85030644529&partnerID=8YFLogxK

U2 - 10.3949/ccjm.84gr.17006

DO - 10.3949/ccjm.84gr.17006

M3 - Article

C2 - 28985176

AN - SCOPUS:85030644529

SN - 0891-1150

VL - 84

SP - 759

EP - 767

JO - Cleveland Clinic journal of medicine

JF - Cleveland Clinic journal of medicine

IS - 10

ER -

Diabetes medications and cardiovascular outcome trials: Lessons learned

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this